VJHemOnc Podcast
The VJHemOnc podcast, from the Video Journal of Hematology and Hematological Oncology, delivers the latest news and insights in hematology and hematological oncology from international experts. It covers a wide range of topics, including leukemias, lymphomas, MDS, MPNs, sickle cell, aplastic anemia, and rare diseases. Aimed at healthcare professionals and researchers, the podcast offers cutting-edge trial updates, controversies, and expert opinion on an independent, open-access platform. Listeners can also visit the accompanying website for more news and resources.
Episodes
Future perspectives in frontline MCL treatment and management: a European and US view
This VJHemOnc podcast episode explores future directions in frontline mantle cell lymphoma (MCL) treatment, focusing on the evolving role of chemotherapy, BTK inhibitors, and autologous stem cell transplantation. Mats Jerkeman, MD, PhD, Lund University, Lund, Sweden, shares a European perspective on changing frontline treatment standards, including the implications of the TRIANGLE and ECHO trials
Novel targets, combinations, and treatments in AML: highlights from iwAL 2026
This episode of the VJHemOnc podcast features an exclusive expert-led roundtable discussion summarizing two sessions from the 8th International Workshop on Acute Leukemias (iwAL 2026) that focused on novel targets, combinations, and treatments in acute myeloid leukemia (AML). This session is chaired by Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, who is joined by panelists Sanam Logh
IMS 2026 highlights: advances in multiple myeloma treatment and the path towards cure
In this episode of the VJHemOnc podcast, experts discuss key advances in multiple myeloma presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026) in Glasgow, UK. Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, reviews long-term outcomes from the Phase III PERSEUS trial (NCT03710603), while Zachary Avigan, MD, Icahn School of Medicine at Mo
Personalizing BTK Inhibitor Therapy in CLL: from treatment selection to long-term management
This VJHemOnc podcast explores how BTK inhibitor therapy can be personalized for patients with chronic lymphocytic leukemia (CLL), considering disease biology, patient characteristics and treatment goals.
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses frontline treatment selection, molecular risk and factors influencing BTK inhibitor choice, while Florian Simon, MD, Unive
Using BTK inhibitors in lymphoma: practical considerations for community physicians
This episode of the VJHemOnc podcast, featuring Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, focuses on the practical use of BTK inhibitors (BTKis) in non-Hodgkin lymphoma (NHL). Dr Kamdar begins by discussing which factors guide patient selection for BTKi therapy and outlines how to choose among available agents. She then shares valuable insights on toxicity management, ap
AAV gene therapy in hemophilia: progress, challenges and what comes next
This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of AAV-based approaches and the development of next-generation strategies.
Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, discusses the limitations of AAV gene therapy in hemophilia A, including factor VIII engineering, durability, and liver toxicity. He al
Clinical considerations in MCL management: frailty assessment, the multidisciplinary team & managing the use of BTKis
This VJHemOnc podcast explores the evolving management of mantle cell lymphoma (MCL), from assessing patient fitness to sequencing therapy after BTK inhibitor progression. Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, and Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI, discuss assessing fitness and frailty, while Craig Portell, MD, University of Virginia, Charlottesville, VA, outl
Sequencing therapies in multiple myeloma: navigating an expanding treatment landscape
This VJHemOnc podcast explores the evolving treatment landscape in multiple myeloma, focusing on treatment selection and sequencing across the disease course. Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses shared decision-making in frontline treatment, while Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, explores sequencing CAR T-cell therapies and bisp
The evolving treatment landscape in ALL: the growing role of immunotherapy and reduced reliance on chemotherapy
There has been a significant shift in the treatment of acute lymphoblastic leukemia (ALL), driven by the emergence of novel immunotherapies. In this episode, leading experts explore how these advances are changing the treatment landscape and where the field is headed next. First, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, outlines emerging treatment strategies for ALL and
Precision medicine in MDS: tailoring treatment through molecular profiling
This VJHemOnc podcast explores how precision medicine is reshaping the management of myelodysplastic syndromes (MDS). Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses whole genome sequencing, patient selection for venetoclax-based therapy, and the future of precision medicine following the VERONA trial (NCT04401748). Pinkal Desai, MD, MPH, Weill Cor
The current and future role of BTK inhibitors across non-Hodgkin lymphoma subtypes
This episode of the VJHemOnc podcast explores the current and future role of BTK inhibition across several non-Hodgkin lymphoma (NHL) subtypes.
First, Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, Steven Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA, and Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, provide insight in
The diagnosis and management of hematologic malignancies during pregnancy
In this episode of the VJHemOnc podcast, Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, shares insight into the diagnosis and management of hematologic malignancies during pregnancy. Dr Dierickx comments on common misconceptions clinicians may have when treating this patient population and outlines key principles and factors that guide clinical decisions for pr
Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse
This VJHemOnc podcast explores the latest advances in Hodgkin lymphoma, from evolving frontline treatment strategies to emerging approaches in relapsed and refractory disease. Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the final three-year results from the AVENUE study (NCT03617666) and the role of circulating tumor DNA (
Sequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies
This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment options following covalent BTK inhibitor therapy, including venetoclax-based regimens and non-covalent BTK inhibitors. Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Verc
Precision medicine in AML: from targeted therapy to transplantation
This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted therapies, measurable residual disease (MRD) assessment, and transplantation. Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the Phase I/II KOMET-007 study (NCT05735184) evaluating ziftomenib in combination w
MPNs in focus: disease progression, risk assessment, and emerging treatments
This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses mechanisms of disease progression, the DUSP6-RSK1 signaling pathway as a therapeutic target, and the ongoing debate around early v
The evolving role of cellular therapies and T-cell engagers in lymphoma
This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, to discuss novel cellular therapy strategies, including NK-cell thera
Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure
This VJHemOnc podcast explores how evolving treatment strategies, immunotherapies, and MRD-driven approaches are reshaping the management of multiple myeloma and precursor disease. Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses early intervention strategies in smoldering myeloma and presents findings from the CAR-PRISM study (NCT05767359) evaluating cilta-cel in high-risk
Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy
This VJHemOnc podcast features a roundtable discussion from the 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) 2026 on the evolving role of dual-targeting CAR T-cell therapies in large B-cell lymphoma (LBCL). Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, is joined by Saurabh Dahiya, MD, FACP, Stanford University School of Medicine, Stanford, CA, Ni
Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation
This VJHemOnc podcast explores the latest advances in gene-based therapies for sickle cell disease (SCD) and thalassemia, highlighting progress in patient access, selection, treatment delivery, and clinical outcomes. Sunil Gupta, MD, FRCP, FRCPath, MBA, Lewisham and Greenwich NHS Trust, London, UK, discusses expanding access to gene therapy for patients with SCD, while Alexander Ngwube, MD,
The evolving role of BTK inhibitors in CLL
Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians
In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the main factors contributing to the observed reduction in the incidence of higher-grade CRS and ICANS following CAR-T. Following this, Eleftheria Kampouri, MD, University of Lausanne,
The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care
This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chemo‑free regimens and the growing role of BTK inhibitors.
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of frontline treatment in achieving long-term disease control. You will also hear from Da
Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies
This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents.
Experts discuss the growing importance of donor germline genetics, updated guidance for Hodgkin lymphoma transplantation, the shifting role of CAR T‑cell therapy in non‑Hodgkin lymphoma, and
Myeloid Monthly: breaking news & updates from the classification advancement meeting
This VJHemOnc podcast introduces the first edition of Myeloid Monthly, focusing on key developments in myeloid malignancies. Amer Zeidan, MD, Yale University, New Haven, CT, is joined by Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Sanam Loghavi, MD, MD Anderson Cancer Center, Houston, TX, to discuss breaking updates from the Classification Advancement Meeting (CAM), held
How AI is transforming hematologic oncology
This VJHemOnc podcast explores how artificial intelligence (AI) is transforming hematologic oncology, from clinical research and diagnostics to risk prediction and therapy development. Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses AI-driven approaches to improving clinical trial enrollment, while Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, highlights advances in AI-based pat
MRD in ALL and AML: from prognostic marker to clinical endpoint
This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the potential of MRD as a surrogate endpoint in AML, while Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, presents supporting
Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026
Nurses play a key role in the CAR T-cell therapy process. In this podcast episode, you will hear insights into nursing in CAR-T and cellular therapy through exclusive interviews from the recent EBMT-EHA 8th European CAR T-cell Meeting.
First, Erik Aerts, RN, University of Zurich, Zurich, Switzerland, will walk through the CAR T-cell process from a nursing perspective, and Mairéad Ní Chonghaile,
Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes
Today’s episode of the VJHemOnc podcast features updates from a number of clinical trials exploring BTK inhibitors (BTKi) and BTKi-containing regimens in non-Hodgkin lymphoma (NHL) that were presented at the 2025 ASH Annual Meeting.
First, you will hear updates in mantle cell lymphoma (MCL) trials from Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Austin Kim, M
ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD
This VJHemOnc podcast highlights key AL amyloidosis updates from ASH 2025, spanning risk stratification, optimisation of frontline therapy, emerging immunotherapies, and MRD assessment. Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, discusses a newly validated staging system defining ultra-high-risk AL amyloidosis in the era of daratumumab-base
Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies
This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH 2025, spanning frontline therapy, molecularly targeted approaches, venetoclax-based combinations, and emerging immunotherapies. Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the Phase II PARADIGM study (NCT04801797) comparing azacitidine plus venetoclax with intensive chemotherapy, along
Managing and preventing differentiation syndrome in APL
In this episode of the VJHemOnc Podcast, we focus on the management and prevention of differentiation syndrome in acute promyelocytic leukemia (APL). We begin with a discussion with Yasmin Abaza, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, on the biological basis of differentiation syndrome, the rationale and mechanism behind steroid prophylaxis, and how the supporting ev
Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more
This podcast highlights key non-Hodgkin lymphoma (NHL) updates from ASH 2025 across follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. John Burke, MD, Rocky Mountain Cancer Centers, Denver, CO, presents the MorningSun study (NCT05207670) of subcutaneous mosunetuzumab in previously untreated FL, while Lorenzo Falchi, MD,
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T, trispecific antibodies, and more!
This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses redefining functional high-risk myeloma, followed by Nisha Joseph, MD, Winship Cancer Institute, Emory University, Atlanta, GA, who shares results from a Phase II dose-optimization study (NCT04068597) of inobrodib with pomalidomide and dexamethasone.
Update
Top CLL updates from ASH 2025: novel BTKi monotherapy and combination approaches, BTK degraders, & more
This podcast features updates in chronic lymphocytic leukemia (CLL) from ASH 2025. Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the Phase III FLAIR study (ISRCTN01844152), followed by Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, who shares further insights.
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denm
Top updates in MDS from ASH 2025: key trial updates and debated topics
In this podcast episode, leading experts share key updates in the management of myelodysplastic syndromes (MDS) from ASH 2025. Amer Zeidan, MBBS, MHS, Yale School of Medicine, New Haven, CT, highlights data from the MAXILUS trial (NCT06045689), new insights from the IMerge study (NCT02598661), and early findings with bexmarilimab in higher-risk MDS (HR-MDS). This is followed by Valeria Santini, MD
Sickle cell disease management: navigating the transition from pediatric to adult care, managing VOCs, & more
In this podcast episode, leading experts provide valuable insight into the management of sickle cell disease (SCD). First, Samah Babiker, MBBS, MRCP-UK, FRCPath, Evelina London Children’s Hospital, London, UK, and Payal Desai, MD, Levine Cancer Institute & Wake Forest School of Medicine, Charlotte, NC, discuss the challenges associated with the transition from pediatric to adult care and how t
Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges
This episode of the VJHemOnc podcast focuses on accelerated and blast-phase myeloproliferative neoplasms (MPN-AP/BP), offering insights into their diagnosis and management from leading experts.
First, in an interview with Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, you will hear about the diagnosis, risk stratification, and therapeutic strategies being explored for patient
The value and utility of MRD in the management of adults with newly-diagnosed AML
This podcast features experts Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, who debate the value and utility of measurable residual disease (MRD) in the management of adults with newly-diagnosed acute myeloid
Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance
This episode of the VJHemOnc Podcast features discussions from the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC. First, you will hear from Ross Firestone, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Nisha Joseph, MD, Winship Cancer Institute of Emory University, Atlanta, GA, and Ajai Chari, MD, University of California San F
Advances in immunotherapy for NHL: updates from iwNHL 2025
This podcast features discussions from the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL), which took place in Cambridge, MA. The discussions focus on immunotherapy and novel combinations being explored for the treatment of NHL. Featuring experts Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Lorenzo
Reviewing recent guideline updates on the risk stratification and treatment of AML
In this episode of the VJHemOnc Podcast, we are joined by Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, and Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, to discuss recent guideline updates on the risk stratification and treatment of acute myeloid leukemia (AML). The experts discuss differences in the World Health Organization (WHO) and International Consensus Classifi
The management of CLL in resource-limited settings: guideline development and ongoing projects
VJHemOnc recently attended the International Workshop on Chronic Lymphocytic Leukemia (XXI iwCLL 2025) in Krakow, Poland, where there was a session focused on the management of CLL in resource-limited settings. Today's podcast episode highlights discussions from this session. First, you will hear from Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, who discusses the develo
The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist
This episode of our Blood Cancer Awareness Month series explores the role of the multi-disciplinary team in caring for patients with blood cancer undergoing CAR T-cell therapy.
The discussion features insights from Ty Simpson, BN, MNP, Alfred Health, Melbourne, Australia, who is a CAR-T nurse practitioner, and Frederick Vonberg, MD, University College London Hospitals NHS Foundation Trust, London,
Understanding financial and time toxicity in cancer care: advice for community oncologists
Welcome to the next episode in our Blood Cancer Awareness Month series. In this podcast, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses financial and time toxicities in cancer care, explaining how out-of-pocket costs and the time spent receiving treatment impair patients' lives. Dr Banerjee shares insights from his own clinical experience, with a focus on patients
Listener Q&A special: expert insights on CLL, myeloma, and lymphoma
Welcome to the first episode of our Blood Cancer Awareness Month special on VJHemOnc. In this podcast, leading experts answer your most pressing questions on blood cancers. Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses chronic lymphocytic leukemia (CLL), followed by Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, who addres
Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025
This episode features discussions from the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal. First, you will hear from Uma Borate, MD, The Ohio State University, Columbus, OH, Luca Lanino, MD, PhD, Yale University, New Haven, CT, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Zoey X
Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials
This episode of the VJHemOnc Podcast spotlights advances in the understanding and treatment of Waldenström’s macroglobulinemia (WM), featuring Karan Chohan, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, Neil Berinstein, MD, Sunnybrook Odette Cancer Centre
FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD
This podcast focuses on FLT3-ITD-positive acute myeloid leukemia (FLT3-ITD+ AML), featuring experts Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Harry Erba, MD, PhD, Duke University, Durham, NC. The episode covers th
Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial
In this episode of the VJHemOnc Podcast, we dive into one of the more aggressive and challenging manifestations of multiple myeloma, extramedullary disease (EMD). We are joined by experts Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, Saurabh Zanwar, MD, MBBS, Mayo Clinic, Rochester, MN, and Shaji Kumar, MD, Ma
iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more
In this week’s VJHemOnc podcast, we’ll be sharing highlights in myeloproliferative neoplasms (MPNs) from the recent 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025. First, you will hear a roundtable discussion, in which Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Donal McLornan, MB, BCh, MR
Managing CNS lymphoma: expert insights and updates from ICML 2025
In this episode of the VJHemOnc podcast, we are joined by experts Kathryn Tringale, MD, UC San Diego Health, San Diego, CA, and Nikita Dave, MD, University of Pennsylvania, Philadelphia, PA, who share their perspectives on the management of patients with central nervous system (CNS) lymphoma from the 18th International Conference on Malignant Lymphoma (ICML 2025). The discussion covers both primar
iwMDS wrap-up: translating research into practice to optimize patient care
VJHemOnc recently attended the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal. This episode features experts Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, Elizabeth Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Lisa Pleyer, MD, Paracelsus Medical U
Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification
Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a trending topic in the field! You will hear leading experts Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discuss wha
Treating elderly or unfit patients with AML: current approach and future directions
This episode of the VJHemOnc podcast focuses on the treatment of elderly or unfit patients with acute myeloid leukemia (AML). Featuring experts Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Joshua Zeidner, MD, UNC Linebe
Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!
VJHemOnc recently attended the 2025 ASCO Annual Meeting in Chicago, IL, where we gained insights into the latest advancements in hematologic oncology. In this episode, leading experts Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Manali Kamdar, MD, University of Co
CHIP & CCUS: advances in understanding and should we treat these precursor conditions?
In this episode of the VJHemOnc podcast, we explore clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - conditions increasingly recognized as early indicators of myelodysplastic syndromes and acute myeloid leukemia.
Joining the discussion are leading experts George Vassiliou, MBBS, PhD, The University of Cambridge, Cambridge, UK, Sanam Logha
Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain
In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a leading expert in the field, to discuss the complexities surrounding the diagnosis of amyloidosis, including both the light chain and ATTR subtypes.
The conversation covers early clinical signs that clinicians often overlook, key differences in presentation between subtypes, recommendatio
IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more
VJHemOnc was the official media partner for the recent 2nd International PNH Interest Group (IPIG) Conference held in Paris, France. In today’s podcast episode, you will hear some highlights from the event from leading experts in the field of paroxysmal nocturnal hemoglobinuria (PNH).
First, Jens Panse, MD, Aachen University Hospital, Aachen, Germany, Richard Kelly, MBChB, PhD, St James’s Universi
Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease
In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Dr Collins discusses the significant shifts in treatment approaches for patients with advanced-stage classical Hodgkin lymphoma over the past decade. He also explores the excitement around newer regimen
Gene therapy in sickle cell disease: patient selection, potential complications, & more
In this episode of the VJHemOnc podcast you will hear from Akshay Sharma, MBBS, MSc, St. Jude Children’s Research Hospital, Memphis, TN, who takes a deep dive into gene therapy for the treatment of sickle cell disease (SCD). Dr Sharma begins by discussing the status of gene therapy in SCD, outlining considerations for clinicians when selecting patients for these therapies, and commenting on the ri
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community
Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently in Miami, FL. First you will hear from Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Mohammad Rashidian, PhD, Dana-Farber Cancer Institute, Boston, MA, Michael Jain, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Ma
Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy
This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, who provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations. They explore treatment strategies at first relaps
Highlights from iwMyeloma 2025: trial updates and practical considerations
VJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL. This podcast episode features highlights from the meeting.
First, you will hear from Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Thomas Martin, MD, University of California San
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). Th
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more
In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation.
Tune in as experts Mohamad Mohty, MD, PhD, Sa
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more!
This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). They focus on the sequencing
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms
CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cell product. This episode also covers studies of tri
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Curtis Lachowiez, MD, Ore
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance
BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients.
In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, Adria
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!
In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and patient care, offering insights and strategies for healthcare professionals to address them. The discussion centers on four topics: the treatment of smoldering myeloma, managing frail and elderly patients, challenges in triple-class refractory disease, and racial d
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes
CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly changed the therapeutic landscape for patients. In this podcast episode, renowned experts will share insight into the use of CAR-T in ALL, including updates of pivotal trials, novel approaches being explored, and real-world outcomes.
Fir
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis from the meeting, including updates from the ANDROME
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia
This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts.
First, Sophia Delicou, MD, Hippokration General Hospital, Athens, Greece, will
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, Alexander Lesokhin, MD, Memorial
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML
In this podcast, we bring you exclusive updates on acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
This podcast episode covers key highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
Today's podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia Ruan, MD, PhD, Weill Cornell Medical College, New
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS).
You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park, MD, CHU Grenoble Alpes, Grenoble, France, Esther
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today's episode focuses on chronic lymphocytic leukemia (CLL).
You will hear from experts Jeff Sharman, MD, Willame
Recommended
The Rest Is History
Who We Are Now with Izzy & Richard Hammond
True Crime Investigators UK
Uk Mix RadioShow
CAA on General Aviation
Pod Save The King
Pride and Prejudice (version 6, dramatic reading)
InsideAIR
English Made Simple
Golden's Oldies
The CTO Lens
RHISE: Real History in Simple English (B2-C1, British)
